文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

阿巴西普、森西韦罗或英夫利西单抗治疗成人COVID-19肺炎住院患者:一项随机临床试验

Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

这项随机、双盲、安慰剂对照试验在美国和拉丁美洲95家医院85个临床研究点开展,纳入1971例确诊SARS-CoV-2感染且肺部受累的住院成人,比较阿巴西普、森西韦罗或英夫利西单抗联合标准治疗与安慰剂的疗效。主要终点28天恢复时间在三组与安慰剂间均无显著差异;28天全因死亡率阿巴西普组11.0% vs 安慰剂组15.1%(OR 0.62),英夫利西单抗组10.1% vs 安慰剂组14.5%(OR 0.59),森西韦罗组13.8% vs 安慰剂组11.9%(OR 1.18)。

要点

  • 阿巴西普、森西韦罗或英夫利西单抗联合标准治疗均未显著缩短COVID-19肺炎住院患者28天恢复时间。
  • 28天全因死亡率:阿巴西普组11.0% vs 安慰剂组15.1%(OR 0.62),英夫利西单抗组10.1% vs 安慰剂组14.5%(OR 0.59)。
  • 森西韦罗组28天全因死亡率13.8% vs 安慰剂组11.9%(OR 1.18),与安慰剂无显著差异。

核心结论

  • 住院COVID-19肺炎患者中,阿巴西普、森西韦罗或英夫利西单抗与安慰剂相比,28天恢复时间均无显著差异。

研究设计与样本

  • 随机、双盲、安慰剂对照临床试验,采用主方案研究免疫调节剂联合标准治疗对COVID-19肺炎住院患者的疗效。
  • 报告3项子研究结果,来自美国及拉丁美洲85个临床研究点的95家医院。
  • 纳入18岁及以上、确诊SARS-CoV-2感染14天内且有肺部受累证据的住院患者,2020年10月至2021年12月随机分组。
  • 干预:阿巴西普单次输注10 mg/kg(最大剂量1000 mg);英夫利西单抗单次输注5 mg/kg;森西韦罗口服28天(300 mg负荷剂量后150 mg每日两次)。
  • 共1971例随机分组,平均(SD)年龄54.8(14.6)岁,1218例(61.8%)为男性。

主要发现

  • 主要终点28天恢复时间:阿巴西普恢复率比(RRR)1.12(95%CI 0.98-1.28;P=0.09),与安慰剂无显著差异。
  • 森西韦罗RRR 1.01(95%CI 0.86-1.18;P=0.94),与安慰剂无显著差异。
  • 英夫利西单抗RRR 1.12(95%CI 0.99-1.28;P=0.08),与安慰剂无显著差异。
  • 28天全因死亡率:阿巴西普组11.0% vs 安慰剂组15.1%(OR 0.62,95%CI 0.41-0.94)。
  • 28天全因死亡率:森西韦罗组13.8% vs 安慰剂组11.9%(OR 1.18,95%CI 0.72-1.94);英夫利西单抗组10.1% vs 安慰剂组14.5%(OR 0.59,95%CI 0.39-0.90)。

关键数值与推荐

  • 恢复定义为参与者首次在8分序数量表上评分至少为6分的那一天,评分越高表示健康状况越好。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Immune dysregulation contributes to poorer outcomes in COVID-19. OBJECTIVE: To investigate whether abatacept, cenicriviroc, or infliximab provides benefit when added to standard care for COVID-19 pneumonia. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-masked, placebo-controlled clinical trial using a master protocol to investigate immunomodulators added to standard care for treatment of participants hospitalized with COVID-19 pneumonia. The results of 3 substudies are reported from 95 hospitals at 85 clinical research sites in the US and Latin America. Hospitalized patients 18 years or older with confirmed SARS-CoV-2 infection within 14 days and evidence of pulmonary involvement underwent randomization between October 2020 and December 2021. INTERVENTIONS: Single infusion of abatacept (10 mg/kg; maximum dose, 1000 mg) or infliximab (5 mg/kg) or a 28-day oral course of cenicriviroc (300-mg loading dose followed by 150 mg twice per day). MAIN OUTCOMES AND MEASURES: The primary outcome was time to recovery by day 28 evaluated using an 8-point ordinal scale (higher scores indicate better health). Recovery was defined as the first day the participant scored at least 6 on the ordinal scale. RESULTS: Of the 1971 participants randomized across the 3 substudies, the mean (SD) age was 54.8 (14.6) years and 1218 (61.8%) were men. The primary end point of time to recovery from COVID-19 pneumonia was not significantly different for abatacept (recovery rate ratio [RRR], 1.12 [95% CI, 0.98-1.28]; P = .09), cenicriviroc (RRR, 1.01 [95% CI, 0.86-1.18]; P = .94), or infliximab (RRR, 1.12 [95% CI, 0.99-1.28]; P = .08) compared with placebo. All-cause 28-day mortality was 11.0% for abatacept vs 15.1% for placebo (odds ratio [OR], 0.62 [95% CI, 0.41-0.94]), 13.8% for cenicriviroc vs 11.9% for placebo (OR, 1.18 [95% CI 0.72-1.94]), and 10.1% for infliximab vs 14.5% for placebo (OR, 0.59 [95% CI, 0.39-0.90]). Safety outcomes were comparable between active treatment and placebo, including secondary infections, in all 3 substudies. CONCLUSIONS AND RELEVANCE: Time to recovery from COVID-19 pneumonia among hospitalized participants was not significantly different for abatacept, cenicriviroc, or infliximab vs placebo. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04593940.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. O'Halloran JA, Ko ER, Anstrom KJ, et al. Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA. 2023. PMID: 37428480. doi:10.1001/jama.2023.11043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。